GS
CARM

GTS Securities’s Carisma Therapeutics CARM Stock Holding History

GTS Securities’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,118
Closed -$13.7K – 1426
2025
Q3 		$13.7K Hold
50,118
– – ﹤0.01% 1392
2025
Q2 		$19.6K Buy
+50,118
New +$13.4K ﹤0.01% 1183

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

GTS Securities's CARM Position: Q4 2025 in Review

GTS Securities sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 50,118 shares — an estimated $13.7K sold.

GTS Securities first reported a position in CARM in Q2 2025 and held it in 2 quarters. The position peaked at $19.6K in Q2 2025. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • GTS Securities reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GTS Securities sold 50,118 Carisma Therapeutics shares in Q4 2025, an estimated $13.7K.
  • GTS Securities first reported a position in Carisma Therapeutics in Q2 2025 and held it in 2 quarters.
  • GTS Securities's Carisma Therapeutics position peaked at $19.6K in Q2 2025.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on GTS Securities's 13F filing for Q4 2025, filed 13 Feb 2026.